<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>reimbursement on Health Insights</title>
    <link>https://celebrated-fenglisu-226492.netlify.app/en/tags/reimbursement/</link>
    <description>Recent content in reimbursement on Health Insights</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en</language>
    <lastBuildDate>Thu, 15 Jul 2021 00:00:00 +0000</lastBuildDate><atom:link href="https://celebrated-fenglisu-226492.netlify.app/en/tags/reimbursement/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>A closer look at reimbursement Pathways for Prescription Digital therapeutics</title>
      <link>https://celebrated-fenglisu-226492.netlify.app/en/blog/reimbursement-path/</link>
      <pubDate>Thu, 15 Jul 2021 00:00:00 +0000</pubDate>
      
      <guid>https://celebrated-fenglisu-226492.netlify.app/en/blog/reimbursement-path/</guid>
      <description>Picture courtesy of ilt-engineering.de Current Reimbursement schemes Like all new health technology, once Digital Therapeutics DTx products receive regulatory approval, they are subject to a health technology assessment (HTA). This assessment is critical to help inform decisions on its use and reimbursement status based on the added value and position in the care continuum. &amp;ldquo;HTA comprises systematic, multidisciplinary evaluation, taking in the description, examination, and appraisal of healthcare, as well as the short- or long-term economic, social and ethical implications directly or indirectly related to existing and newly introduced health technologies .</description>
    </item>
    
  </channel>
</rss>
